---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-137210"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:06:19.546498+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences Q1 net loss $0.16/shr; cash $30.4M; FB102 SAD completed, MAD ongoing

## Summary
- Net loss $7.4M ($0.16/shr) vs $6.8M ($0.32/shr) in Q1 2023; weighted avg shares 46.1M (incl. pre-funded warrants).
- R&D expense $4.4M (down $0.4M); G&A $3.5M (up $1.4M on legal/professional costs).
- Cash & equivalents $30.4M at Mar 31, 2024, down from $37.1M at Dec 31, 2023.
- FB102 Phase 1 SAD completed; MAD cohorts expected to complete mid-2024; patient studies planned before year-end.
- Company updated corporate presentation (Exhibit 99.2) for investor meetings.

## SEC filing metadata
- accession: 0001193125-24-137210
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312524137210/0001193125-24-137210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312524137210/d825808d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-137210
- JSON: https://secwatch.observer/filing/0001193125-24-137210.json
- Plain text: https://secwatch.observer/filing/0001193125-24-137210.txt

## Key facts
- Earnings Releases
  Forte Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income $(7,420 ), EPS $(0.16 ).
  - Period: the quarter ended March 31, 2024
  - Net income: $(7,420 )
  - EPS: $(0.16 )
  - Result: reported results
  source text: On May 13, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312524137210/0001193125-24-137210-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.